ProfileGDS5678 / 1429003_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 90% 90% 90% 89% 93% 92% 91% 91% 90% 91% 90% 91% 92% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.105590
GSM967853U87-EV human glioblastoma xenograft - Control 27.2182190
GSM967854U87-EV human glioblastoma xenograft - Control 37.2186390
GSM967855U87-EV human glioblastoma xenograft - Control 47.3696690
GSM967856U87-EV human glioblastoma xenograft - Control 57.1047289
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.575293
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.4582492
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.3227291
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.4429391
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.2049490
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.3053491
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.3661990
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.3505691
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.5043492